Online inquiry

IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ98MR)

This product GTTS-WQ98MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ98MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13293MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ4162MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ15815MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ1196MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ3898MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ6458MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ13469MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ5359MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD38-Attenukine
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW